1. Home
  2. NCMI vs PRME Comparison

NCMI vs PRME Comparison

Compare NCMI & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$3.06

Market Cap

306.0M

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$2.98

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCMI
PRME
Founded
2005
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.0M
536.4M
IPO Year
2006
2022

Fundamental Metrics

Financial Performance
Metric
NCMI
PRME
Price
$3.06
$2.98
Analyst Decision
Buy
Buy
Analyst Count
4
6
Target Price
$5.63
$7.56
AVG Volume (30 Days)
267.3K
2.2M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
3.36%
N/A
EPS Growth
52.17
18.18
EPS
N/A
N/A
Revenue
N/A
$4,632,000.00
Revenue This Year
$11.20
$7.06
Revenue Next Year
$6.22
$47.01
P/E Ratio
N/A
N/A
Revenue Growth
N/A
55.28
52 Week Low
$2.80
$1.18
52 Week High
$5.56
$6.94

Technical Indicators

Market Signals
Indicator
NCMI
PRME
Relative Strength Index (RSI) 40.43 38.65
Support Level $2.86 N/A
Resistance Level $3.76 $3.97
Average True Range (ATR) 0.14 0.23
MACD -0.03 -0.02
Stochastic Oscillator 26.98 28.96

Price Performance

Historical Comparison
NCMI
PRME

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: